Patent application number | Description | Published |
20090131528 | SALT - The invention relates to a new salt of aliskiren, the respective production and usage, and pharmaceutical preparations containing such a salt. | 05-21-2009 |
20090156585 | ORGANIC COMPOUNDS - A specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi are used in the treatment of hypertension. | 06-18-2009 |
20090163478 | Salts and Crystal Modifications Thereof - The invention relates to salts of 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea and crystalline forms thereof, their production and usage, and pharmaceutical preparations containing such salts and crystalline forms. | 06-25-2009 |
20110171159 | Glycoside Derivatives and Uses Thereof - This invention relates to compounds represented by formula (I): | 07-14-2011 |
20120178680 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 07-12-2012 |
20130017993 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 01-17-2013 |
20130274279 | CRYSTALLINE FORMS OF 5-CHLORO-N2-(2-ISOPROPOXY-5-METHYL-4-PIPERIDIN-4-YL-PHENYL)-N4-[2-(PROPAN- E-2-SULFONYL)-PHENYL]-PYRIMIDINE-2, 4-DIAMINE - The present invention describes specific crystalline forms of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to methods for preparing said crystalline forms, pharmaceutical compositions comprising said crystalline forms, and methods of using said crystalline forms and pharmaceutical compositions to treat disease. | 10-17-2013 |
20140093570 | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein - The present disclosure relates to crystalline form of (S)āNā((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)āNā((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same. | 04-03-2014 |
20140274921 | GLYCOSIDE DERIVATIVES AND USES THEREOF - This invention relates to compounds represented by formula (I): | 09-18-2014 |